DuraCAR Drug Addresses Major Need in Solid Tumor Therapies
SAN DIEGO, Nov. 10, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) and (OTC PINK: RGBPP)has recently discussed the use of CAR-T therapies in cancer treatment () and its development of a novel approach to creating CAR-T cells that can potentially be used to treat solid tumors ().
The tumor microenvironment contains molecules and cells which can suppress T cells and prevent them from attacking and killing the tumor. "T cell exhaustion" is a term that describes T cells that are initially recruited to a tumor to kill it but end up rapidly losing their effectiveness. Eventually the tumor is surrounded by T cells that are exhausted and ineffective.
The Company has focused on NR2F6, an immune checkpoint which has been convincingly shown to be a very important transcription factor that keeps T cells in check1-4. When this transcription factor is blocked, T cells become very active and can kill tumors much more effectively. The Company has coupled its proprietary shRNA technology, which inhibits NR2F6, with existing CAR-T cell technology to create a potentially durable CAR-T cell which cannot be exhausted by the solid tumor microenvironment. The Company calls this novel CAR-T cell DuraCAR.
"We believe DuraCAR has the characteristics to overcome several of the major hurdles in getting CAR-T cells to be effective in treating solid tumors," says Dr. David Koos Chairman and CEO of the company. "We will know more in the coming months from our experimental work how long the road will be to get our technology fine-tuned to the point where we have a proof-of-concept drug. It is very exciting to see our shRNA technology applied in a way that can potentially help so many people with cancer."
1Klepsch et al. Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapy Cell Communication and Signaling (2020) 18:8.
2Klepsch, V., Hermann-Kleiter, N., Do-Dinh, P. et al. Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade. Nature Communications (2018) 9, 1538.
3Klepsch et. al. Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapy. Immunology Letters (2016) 178, 31-36.
4Hermann-Kleiter, et. al. The Nuclear Orphan Receptor NR2F6 Is a Central Checkpoint for Cancer Immune Surveillance. Cell Reports (2015) 12:12, 2072-2085.
About Regen BioPharma Inc.:
Regen BioPharma, Inc. is a publicly traded biotechnology company (PINK: RGBP) and (PINK: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on mRNA and small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at .
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-722-5505 Phone
+1-619-330-2328 Fax
Follow us on Twitter for future updates:
SOURCE Regen BioPharma, Inc.
